Fig. 5
From: Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
In vivo tumor growth in MDAMB231 xenografts upon sorafenib and/or selumetinib therapy. a Tumor volume was determined twice/weekly using caliper. b Mouse weight loss (%) at day 18, compared to the beginning of the treatment. c Relative tumor volume of MDAMB231 mammary xenografts at day 18. d Tumor weights of MDAMB231 mammary xenografts at day 18. Each group consisted of 10 animals. Data is shown as the mean +/− SEM (*p ≤ 0.05, * * p ≤ 0.01, * * * p ≤ 0.001)